StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Perhexilin

Perhexiline

HCID 4746
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
35193-73-8
Standard-SMILES
C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
InChIKey
CYXKNKQEMFBLER-UHFFFAOYSA-N
Summenformel
C19H35N
Durchschnittliche Molmasse
277,5 g/mol
Monoisotopische Masse
277,27695012

Überblick

Perhexiline is a member of piperidines. It has a role as a cardiovascular drug.

Namen und Bezeichner

Bevorzugter Name
Perhexiline
IUPAC
2-(2,2-dicyclohexylethyl)piperidine
Lokaler Name
Perhexilin
Englischer Name
perhexiline
Summenformel
C19H35N
Molmasse
277.49

Namen und Synonyme

PERHEXILINE2-(2,2-Dicyclohexylethyl)piperidinePerhexilene6621-47-2PerhexilinaPiperidine, 2-(2,2-dicyclohexylethyl)-PerhexilinumDTXSID7023439KU65374X44CHEBI:35553RefChem:860305DTXCID603439
Weitere Namen anzeigen
PerhexillinePerhexiline USP/EP/BPPerhexiline (Mixture of Diastereomers)(S)-2-(2,2-Dicyclohexylethyl)piperidine(R)-2-(2,2-Dicyclohexylethyl)piperidine(2S)-2-(2,2-Dicyclohexylethyl)piperidine(2R)-2-(2,2-Dicyclohexylethyl)piperidine
C08EX02229-569-5Perhexilinum [INN-Latin]Perhexilina [INN-Spanish](+)-2-(2,2-Dicyclohexylethyl)piperidine(-)-2-(2,2-Dicyclohexylethyl)piperidine39648-48-1Perhexiline (INN)

Datenbank-Bezeichner

CAS
35193-73-8、39648-47-0、39648-48-1、6621-47-2
PubChem CID
4746
DTXSID
DTXSID7023439
ChEMBL

Eigenschaften

Berechnete Struktureigenschaften

XLogP
6,8
Polarare Oberfläche (TPSA)
12 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
1
Frei drehbare Bindungen
4
Schwere Atome
20
Formalladung
0
Komplexität
245

Experimentelle und physikochemische Eigenschaften

LogP6.2
Solubility2.72e-05 g/L
Physical DescriptionSolid
Collision Cross Section179.09 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Siedepunkt
340 · 340.0±10.0 °C(Predicted)
Dichte
0.926 · 0.926±0.06 g/cm3(Predicted)
pka
10.36 · pKa 10.36 ± 0.06(40% EtOH,t =25,) (Uncertain)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Exposure RoutesWell absorbed (>80%) from the gastrointestinal tract following oral administration.
Toxicity Summary · 1 Eintrag

Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.

Signs and SymptomsShort term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Perhexiline

vMost-DILI-concern

8

Withdrawn

DOI:10.1016/j.drudis.2016.02.015

Toxicity DataLD50: 2150 mg/kg (Oral, Rat) (A308) LD50: 2641 mg/kg (Oral, Mouse) (A308)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingPerhexiline and its metabolites are highly protein bound (>90%).
Pharmacodynamics · 1 Eintrag

Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.

Mechanism of Action · 1 Eintrag

Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.

Biological Half-LifeVariable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.
Metabolism/Metabolites · 2 Einträge

The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6).

Zugehörige Reaktionen

2
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 479328
HRID 479328als Edukt
Reaktionsgleichung von HRID 2315973
HRID 2315973als Produktals Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CHEMBL75880
ChEBI
CHEBI:35553
UNII
KU65374X44
EC Number
229-569-5、252-426-3、254-558-7、254-559-2
Nikkaji
J261.412J、J261.413H、J8.427A

The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6). Half Life: Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.

MeSH Pharmacological Classification · 3 Einträge

A class of drugs that act by selective inhibition of calcium influx through cellular membranes.

Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and ExcretionWell absorbed (>80%) from the gastrointestinal tract following oral administration.
Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesFor the management of severe angina pectoris.

Anwendungen

VerwendenVasodilator (coronary).

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

HydrogenchloridNatriumhydroxidWasserstoffCyclohexylmagnesium bromideAmeisensäure-ethylesterMaleinsäure